, OMS | Les 10 principales causes de mortalité. WHO. Disponible sur
Direction de la recherche des études de l'évaluation et des statistiques, Santé publique France. L'état de santé de la population en France: rapport 2017. 3. Risque_cardio_vasculaire_rap.pdf. Disponible sur, 2003. ,
La plaque. Médecine Thérapeutique, janv, vol.6, issue.10, pp.810-814, 2001. ,
,
, Haute Autorité de Santé-Principales dyslipidémies : stratégies de prise en charge
ESC/EAS Guidelines for the Management of Dyslipidaemias, Eur Heart J, vol.37, issue.39, pp.2999-3058, 2016. ,
,
Classification of hyperlipidaemias and hyperlipoproteinaemias, Bull World Health Organ, vol.43, issue.6, pp.891-915, 1970. ,
Idiopathic hyperlipemia. Proposition of a simplified classification, Presse Med. avr, vol.79, issue.18, pp.791-796, 1971. ,
Diagnostic et traitement des hypercholestérolémies familiales (HF) chez l'adulte : recommandations de la Nouvelle société française d'athérosclérose (NSFA) ,
Prevalence of dyslipidaemias in a representative sample of the French population, Arch Mal Coeur Vaiss. févr, vol.98, issue.2, pp.127-159, 2005. ,
,
Familial hypercholesterolaemia: A global call to arms, Atherosclerosis. nov, vol.243, issue.1, pp.257-266, 2015. ,
Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, J Clin Lipidol. juin, vol.5, issue.3, pp.9-17, 2011. ,
Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES), Circulation. mars, vol.133, issue.11, pp.1067-72, 2016. ,
Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population, Int J Cardiol. juill, vol.174, issue.3, pp.834-840, 2014. ,
,
, Prevalence and treatment of familial hypercholesterolaemia in Australian communities, Int J Cardiol. avr, vol.185, pp.69-71, 2015.
Familial hypercholesterolemia: A largely underestimated cardiovascular risk, Ann Cardiol Angeiol. mai, 2017. ,
Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication, J Clin Endocrinol Metab, vol.97, issue.11, pp.3956-64, 2012. ,
,
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society, Eur Heart J. déc, vol.34, issue.45, pp.3478-90, 2013. ,
Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit, J Clin Lipidol. sept, vol.9, issue.5, pp.703-711, 2015. ,
, , vol.344, 2012.
arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study, BMJ. sept, vol.343, pp.5497-5497, 2011. ,
Familial hypercholesterolaemia: A model of care for Australasia. Atheroscler Suppl, vol.12, pp.221-63, 2011. ,
The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients, J Clin Lipidol. sept, vol.10, issue.5, pp.1129-1136, 2016. ,
Recommendations for the management of patients with familial hypercholesterolemia, Curr Atheroscler Rep. janv, vol.17, issue.1, p.473, 2015. ,
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review, Am J Epidemiol. sept, vol.160, issue.5, pp.407-427, 2004. ,
Genetic heterogeneity of autosomal dominant hypercholesterolemia, Clin Genet, vol.73, issue.1, pp.1-13, 2007. ,
Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial, Am J Med Genet. juill, vol.128, issue.3, pp.285-93, 2004. ,
Cascade screening for familial hypercholesterolaemia and its effectiveness in the prevention of vascular disease, Br J Diabetes Vasc Dis. juill, vol.9, issue.4, pp.171-175, 2009. ,
Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales, Atherosclerosis. mai, vol.240, issue.1, pp.190-196, 2015. ,
Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects, Atherosclerosis. janv, vol.238, issue.1, pp.101-108, 2015. ,
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands, Lancet Lond Engl. janv, vol.357, issue.9251, pp.165-173, 2001. ,
Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience, Atherosclerosis. mars, vol.239, issue.1, pp.93-100, 2015. ,
Deux tiers des patients atteints d'hypercholestérolémie familiale et éligibles aux séances de LDL-aphérèse ne sont pas traités par LDL-aphérèse : données du registre français, Ann Endocrinol. sept, vol.324, issue.7349, pp.241-243, 2002. ,
Consensus statement on the management of dyslipidaemias in adults, Ann Endocrinol. févr, vol.78, issue.1, pp.43-53, 2017. ,
Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, J Clin Lipidol. juin, vol.5, issue.3, pp.30-37, 2011. ,
Detecting familial hypercholesterolaemia in general practice, Aust Fam Physician. déc, vol.41, issue.12, pp.965-973, 2012. ,
Opportunistic screening for familial hypercholesterolaemia via a community laboratory, Curr Opin Lipidol. avr, vol.29, issue.2, pp.534-541, 2012. ,
Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: A pilot study, J Clin Lipidol. janv, vol.23, issue.4, pp.42-50, 2014. ,
Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study, BMJ. juill, vol.321, issue.7254, p.148, 2000. ,
Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey, Atherosclerosis. sept, vol.252, pp.161-166, 2016. ,
The extent of familial hypercholesterolemia instruction in US schools and colleges of medicine, pharmacy, and osteopathic medicine, J Clin Lipidol. mai, vol.9, issue.3, pp.281-289, 2015. ,
,
, Assessment of physicians' awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PloS One, vol.12, p.183494, 2017.
An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the AsiaPacific region: the « Ten Countries Study, BMJ Open, vol.7, issue.10, p.17817, 2017. ,
Coopération entre médecins généralistes et pharmaciens : une revue systématique de la littérature, Cooperation between general practitioners and pharmacists: a systematic review, Santé Publique. août, vol.25, issue.3, pp.331-372, 2013. ,
Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia, J Clin Lipidol. juill, vol.8, issue.4, pp.390-400, 2014. ,
An online questionnaire survey of UK general practitioners' knowledge and management of familial hypercholesterolaemia, F. Pratiques et opinions des médecins généralistes en matière de prévention, vol.6, p.5, 2016. ,
, Think Again About Cholesterol Survey. Atheroscler Suppl. déc, vol.20, pp.1-5, 2015.
Child-Parent Familial Hypercholesterolemia Screening in Primary Care, N Engl J Med, vol.375, issue.17, pp.1628-1665, 2016. ,
est pas mort : c'est même le support préféré des médecins ,